title: Platelet activation in acute pancreatitis.
abstract: OBJECTIVE
  The aim of this study was to assess the functional state of platelets in patients with mild acute pancreatitis and severe acute pancreatitis (S-AP).
  
  
  METHODS
  The number of platelets and their morphological parameters were measured with Advia 2120. β-Thromboglobulin and platelet factor 4 concentrations were determined by enzyme-linked immunosorbent assay method. To evaluate the expression of platelet glycoproteins, flow cytometry method was used.
  
  
  RESULTS
  At the time of admission, a multiparameter evaluation of the platelets' function in AP patients showed enhanced platelet activation, which was reflected by an increase in the number of large platelets, concentration of degranulation markers (platelet factor 4 and β-thromboglobulin), expression of glycoprotein (Gp) IIb/IIIa, and decreased mean platelet component. Only in S-AP patients at day 1 a decreased number of platelets and high expression of P-selectin and GpIa were observed, which may suggest their prognostic value. At day 30, the procoagulation state was still present in S-AP patients, because of increased platelets and number of large platelets as well as high GpIIb/IIIa expression.
  
  
  CONCLUSIONS
  These results may indicate an important role of platelet activation in the pathogenesis of acute pancreatitis and the development of complications in S-AP.
authors.affiliation: Department of Hematological Diagnostics, Medical University of Bialystok, Bialystok, Poland. joannaosada@interia.pl
authors.forename: Joanna
authors.initials: J
authors.lastname: Osada
authors.forename: Urszula
authors.initials: U
authors.lastname: Wereszczynska-Siemiatkowska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Dabrowski
authors.forename: Milena Izabela
authors.initials: MI
authors.lastname: Dabrowska
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D002939:Ciprofloxacin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D019007:P-Selectin / Q000096:biosynthesis; D010195:Pancreatitis / Q000097:blood* / Q000188:drug therapy; D015539:Platelet Activation / Q000187:drug effects / Q000502:physiology*; D010976:Platelet Count; D010978:Platelet Factor 4 / Q000032:analysis; D010980:Platelet Membrane Glycoproteins / Q000096:biosynthesis; D011379:Prognosis; D012720:Severity of Illness Index; D001620:beta-Thromboglobulin / Q000032:analysis
chemical_list: D000900:Anti-Bacterial Agents; D019007:P-Selectin; D010980:Platelet Membrane Glycoproteins; D001620:beta-Thromboglobulin; D008795:Metronidazole; D010978:Platelet Factor 4; D002939:Ciprofloxacin